Jesper Stentoft

1.8k total citations
52 papers, 974 citations indexed

About

Jesper Stentoft is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Jesper Stentoft has authored 52 papers receiving a total of 974 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 29 papers in Genetics and 12 papers in Rheumatology. Recurrent topics in Jesper Stentoft's work include Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Eosinophilic Disorders and Syndromes (12 papers). Jesper Stentoft is often cited by papers focused on Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Eosinophilic Disorders and Syndromes (12 papers). Jesper Stentoft collaborates with scholars based in Denmark, Germany and Italy. Jesper Stentoft's co-authors include Peter Hokland, Susanne Saußele, Norbert Gattermann, Valentín García‐Gutiérrez, Andreas Hochhaus, Jerald P. Radich, Giuseppe Saglio, Philipp D. le Coutre, David M. Ross and Francis J. Giles and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Jesper Stentoft

47 papers receiving 954 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jesper Stentoft Denmark 16 780 534 283 208 158 52 974
Eduardo Bullorsky Argentina 13 746 1.0× 558 1.0× 335 1.2× 163 0.8× 83 0.5× 34 955
Jiří Mayer Czechia 11 748 1.0× 679 1.3× 320 1.1× 161 0.8× 162 1.0× 48 1.0k
Marianne Rosamilia United States 5 483 0.6× 309 0.6× 215 0.8× 119 0.6× 163 1.0× 7 684
Prajwal Boddu United States 21 734 0.9× 361 0.7× 145 0.5× 371 1.8× 373 2.4× 51 1.2k
Jens Freiberg‐Richter Germany 13 523 0.7× 231 0.4× 123 0.4× 236 1.1× 76 0.5× 27 752
Nathalie Cambier France 14 615 0.8× 725 1.4× 297 1.0× 235 1.1× 385 2.4× 41 1.1k
Stéphanie Harel France 15 315 0.4× 276 0.5× 91 0.3× 190 0.9× 316 2.0× 51 785
Alain Sadoun France 12 432 0.6× 209 0.4× 111 0.4× 249 1.2× 131 0.8× 28 820
Lynda Foltz Canada 15 479 0.6× 611 1.1× 246 0.9× 82 0.4× 342 2.2× 50 824
Abhishek Maiti United States 19 777 1.0× 283 0.5× 68 0.2× 248 1.2× 411 2.6× 131 1.1k

Countries citing papers authored by Jesper Stentoft

Since Specialization
Citations

This map shows the geographic impact of Jesper Stentoft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesper Stentoft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesper Stentoft more than expected).

Fields of papers citing papers by Jesper Stentoft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesper Stentoft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesper Stentoft. The network helps show where Jesper Stentoft may publish in the future.

Co-authorship network of co-authors of Jesper Stentoft

This figure shows the co-authorship network connecting the top 25 collaborators of Jesper Stentoft. A scholar is included among the top collaborators of Jesper Stentoft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesper Stentoft. Jesper Stentoft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hansen, Dennis Lund, Thomas Kristensen, Per Trøllund Pedersen, et al.. (2025). Thrombotic Thrombocytopenic Purpura and Evans Syndrome: Validating and Exploring 20 Years of Routine Hospital Care. Journal of Blood Medicine. Volume 16. 279–292.
2.
3.
Kjærsgaard, Anders, Björn Paulsson, Christen Lykkegaard Andersen, et al.. (2023). Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study. Acta Oncologica. 62(10). 1286–1294. 2 indexed citations
4.
Kjærsgaard, Anders, Bianka Darvalics, Björn Paulsson, et al.. (2022). Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study. European Journal Of Haematology. 109(5). 526–541. 4 indexed citations
5.
Radich, Jerald P., Andreas Hochhaus, Tamás Masszi, et al.. (2021). Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 35(5). 1344–1355. 47 indexed citations
6.
Kreutzman, Anna, Bhagwan Yadav, Tim H. Brümmendorf, et al.. (2019). Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. OncoImmunology. 8(9). e1638210–e1638210. 21 indexed citations
7.
Ross, David M., Tamás Masszi, María Teresa Gómez‐Casares, et al.. (2018). Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. Journal of Cancer Research and Clinical Oncology. 144(5). 945–954. 104 indexed citations
8.
Rajala, Hanna, Perttu Koskenvesa, Tim H. Brümmendorf, et al.. (2017). Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143(8). 1543–1554. 19 indexed citations
9.
Hochhaus, Andreas, Tamás Masszi, Francis J. Giles, et al.. (2017). Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 31(7). 1525–1531. 203 indexed citations
10.
Sommarin, Mikael N.E., Stefan Lang, Christine Karlsson, et al.. (2017). Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 129(17). 2384–2394. 96 indexed citations
11.
Hjorth‐Hansen, Henrik, Jesper Stentoft, Johan Richter, et al.. (2016). Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30(9). 1853–1860. 49 indexed citations
12.
Frederiksen, Henrik, Dóra Körmendiné Farkas, Christian Fynbo Christiansen, et al.. (2015). Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. The Lancet Haematology. 2(7). e289–e296. 18 indexed citations
13.
Randers, Else, et al.. (2012). Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib. Leukemia Research Reports. 1(1). 1–3. 6 indexed citations
14.
Stentoft, Jesper, Peter Hokland, Mette Østergaard, Henrik Hasle, & Charlotte Guldborg Nyvold. (2005). Minimal residual core binding factor AMLs by real time quantitative PCR—Initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leukemia Research. 30(4). 389–395. 42 indexed citations
15.
Østergaard, Mette, Jesper Stentoft, & Peter Hokland. (2004). A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia. Leukemia Research. 28(11). 1213–1215. 13 indexed citations
16.
Stentoft, Jesper, et al.. (2002). Cerebral oedema as a possible complication of treatment with imatinib. The Lancet. 359(9319). 1751–1752. 37 indexed citations
17.
Stentoft, Jesper, Niels Pallisgaard, Eigil Kjeldsen, et al.. (2001). Kinetics of BCR‐ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real‐time polymerase chain reaction. European Journal Of Haematology. 67(5-6). 302–308. 45 indexed citations
18.
Jensen, Mogens Krogh, Preben Johansen, & Jesper Stentoft. (1994). Salvage therapy with low‐dose cytosine arabinoside in refractory or relapsed acute non‐lymphocytic leukaemia:. European Journal Of Haematology. 52(4). 236–239. 7 indexed citations
19.
Stentoft, Jesper, et al.. (1992). Lupus anticoagulant and anticardiolipin antibodies in an obstetric population. Acta Obstetricia Et Gynecologica Scandinavica. 71(8). 605–609. 16 indexed citations
20.
Nielsen, Jørn Flohr, et al.. (1988). Haemoptysis caused by aneurysm of saphenous bypass graft to a coronary artery. Scandinavian Journal of Thoracic and Cardiovascular Surgery. 22(2). 189–191. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eduardo Bullorsky Breakdown of academic impact, for papers by Jiří Mayer Breakdown of academic impact, for papers by Marianne Rosamilia Breakdown of academic impact, for papers by Prajwal Boddu Breakdown of academic impact, for papers by Jens Freiberg‐Richter Breakdown of academic impact, for papers by Nathalie Cambier Breakdown of academic impact, for papers by Stéphanie Harel Breakdown of academic impact, for papers by Alain Sadoun Breakdown of academic impact, for papers by Lynda Foltz Breakdown of academic impact, for papers by Abhishek Maiti
Rankless by CCL
2026